Copyright
©The Author(s) 2021.
World J Gastroenterol. Mar 21, 2021; 27(11): 1064-1075
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1064
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1064
Table 1 Demographic and clinical profile of all candidate patients for liver transplant according to E2, E3 and E4 allele stratification
Variables | APOE2 | APOE3 | APOE4 | P value |
Age (yr) (mean ± SD) | 60.8 ± 7.26 | 60.3 ± 7.19 | 60.3 ± 7.44 | 0.956 |
BMI (mean ± SD) | 27.6 ± 4.36 | 26.4 ± 5.01 | 27.0 ± 4.81 | 0.167 |
Gender (n1 = 179; n2 = 358), n2 (%) | ||||
Male (n1 = 145; n2 = 290) | 52 (17.9) | 193 (66.6) | 45 (15.5) | 0.650 |
Female (n1 = 34; n2 = 68) | 9 (13.2) | 48 (70.6) | 11 (16.2) | |
BMI (n1 = 179; n2 = 358), n2 (%) | ||||
Non-obese (n1 = 137; n2 = 274) | 49 (17.9) | 185 (67.5) | 40 (14.6) | 0.519 |
Obese (n1 = 42; n2 = 84) | 12 (14.3) | 56 (66.7) | 16 (19.0) | |
Etiology (n1 = 179; n2 = 358), n2 (%) | ||||
HCV (n1 = 74; n2 = 148) | 24 (16.2) | 96 (64.9) | 28 (18.9) | 0.357 |
HCV + HCC (n1 = 105; n2= 210) | 37 (17.6) | 145 (69.0) | 28 (13.3) | |
HCC Milan (n1 = 105; n2= 210), n2 (%) | ||||
Within the criteria (n1 = 83; n2 = 166) | 29 (17.5) | 115 (69.3) | 22 (13.2) | 0.885 |
Outside the criteria (n1 = 22; n2 = 44) | 8 (18.2) | 29 (65.9) | 7 (15.9) |
Table 2 Genotypic and allele distribution of apolipoprotein E according to group, hepatitis C virus serology/viral load and severity of liver inflammation by the METAVIR score of the total population
APOE genotype | Group | HCV-RNA | METAVIR | METAVIR | |||||
All | HCV | HCV + HCC | Positive | Negative | ≤ A2F4 | A3F4 | A1F4 | A3F4 | |
n1 (179) | n1 (74) | n1 (105) | n1 (33) | n1 (146) | n1 (80) | n1 (11) | n1 (27) | n1 (11) | |
E2/E2 | 15 (8.4) | 6 (8.1) | 9 (8.6) | 7 (21.2) | 8 (5.5) | 9 (11.2) | 1 (9.1) | 4 (14.8) | 1 (9.1) |
E2/E3 | 25 (14.0) | 9 (12.2) | 16 (15.2) | 3 (9.1) | 22 (15.1) | 11 (13.8) | 2 (18.2) | 4 (14.8) | 2 (18.2) |
E2/E4 | 6 (3.3) | 3 (4.1) | 3 (2.9) | 0 (0.0) | 6 (4.1) | 2 (2.5) | 0 (0.0) | 1 (3.7) | 0 (0.0) |
E3/E3 | 92 (51.4) | 36 (48.6) | 56 (53.3) | 16 (48.5) | 76 (52.0) | 39 (48.8) | 8 (72.7) | 12 (44.5) | 8 (72.7) |
E3/E4 | 32 (17.9) | 15 (20.3) | 17 (16.2) | 5 (15.1) | 27 (18.5) | 14 (17.5) | 0 (0.0) | 3 (11.1) | 0 (0.0) |
E4/E4 | 9 (5.0) | 5 (6.7) | 4 (3.8) | 2 (6.1) | 7 (4.8) | 5 (6.2) | 0 (0.0) | 3 (11.1) | 0 (0.0) |
APOE alleles | n2 (%) | n2 (%) | n2 (%) | n2 (%) | n2 (%) | n2 (%) | n2 (%) | n2 (%) | n2 (%) |
E2 | 61 (17.1) | 24 (16.2) | 37 (17.6) | 17 (25.8) | 44 (15.1) | 31 (19.4) | 4 (18.2) | 13 (24.1) | 4 (18.2) |
E3 | 241 (67.3) | 96 (64.9) | 145 (69.1) | 40 (60.6) | 201 (68.8) | 103 (64.4) | 18 (81.8) | 31 (57.4) | 18 (81.8) |
E4 | 56 (15.6) | 28 (18.9) | 28 (13.3) | 9 (13.6) | 47 (16.1) | 26 (16.2) | 0(0.0) | 10 (18.5) | 0 (0.0) |
All | 358 | 148 | 210 | 66 | 292 | 160 | 22 | 54 | 22 |
Table 3 METAVIR scores for liver inflammation in pre-orthotopic liver transplantation patients according to E2, E3 and E4 alleles stratification
METAVIR score | APOE2 | APOE3 | APOE4 | ||||||
Yes | No | Yes | No | Yes | No | ||||
n2 (%) | n2 (%) | P value | n2 (%) | n2 (%) | P value | n2 (%) | n2 (%) | P value | |
METAVIR (n1 = 38; n2 = 76) | |||||||||
A1F4 (n1 = 27; n2 = 54) | 13 (24.1) | 41 (75.9) | 0.764 | 31 (57.4)3 | 23 (42.6) | 0.064 | 10 (18.5) | 44 (81.5) | 0.055 |
A3F4 (n1 = 11; n2 = 22) | 4 (18.2) | 18 (81.8) | 18 (81.8) | 4 (18.2) | 0 (0.0)1 | 22 (100.0) | |||
METAVIR (n1 = 91; n2 = 182) | |||||||||
≤ A2F4 (n1 = 80; n2 = 160) | 31 (19.4) | 129 (80.6) | 1.000 | 103 (64.4)4 | 57 (35.6) | 0.148 | 26 (16.2) | 134 (83.8) | 0.048a |
A3F4 (n1 = 11; n2 = 22) | 4 (18.2) | 18 (81.8) | 18 (81.8) | 4 (18.2) | 0 (0.0)2 | 22 (100.0) |
Table 4 Association of the models for end-stage liver disease score and variables in pre-orthotopic liver transplantation patients according to E2, E3 and E4 allele stratification
Variables | MELD≤ 25 | MELD> 25 | MELD≤ 25 | MELD> 25 | ||||||||||
APOE2 | APOE3 | APOE4 | APOE2 | APOE3 | APOE4 | APOE4 | APOE4 | |||||||
(Yes) | (No) | (Yes) | (No) | |||||||||||
n2 (%) | n2 (%) | n2 (%) | P value | n2 (%) | n2 (%) | n2 (%) | P value | n2 (%) | n2 (%) | P value | n2 (%) | n2 (%) | P value | |
METAVIR (n1 = 38; n2 = 76) | ||||||||||||||
A1F4 (n1 = 27; n2 = 54) | 9 (20.4) | 27 (61.4)3 | 8 (18.2) | 0.085 | 4 (40.0) | 4 (40.0) | 2 (20.0) | NA | 8 (18.2) | 36 (81.8) | 0.044a | 2 (20.0) | 4 (80.0) | NA |
A3F4 (n1 = 11; n2 = 22) | 4 (18.2) | 18 (81.8) | 0 (0.0)3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 22 (100.0) | 0 (0.0) | 0 (0.0) | ||||
METAVIR (n1 = 91; n2 = 182) | ||||||||||||||
≤ A2F4 (n1 = 80; n2 = 160) | 26 (18.6) | 92 (65.7)4 | 22 (15.7) | 0.123 | 5 (25.0) | 11 (55.0) | 4 (20.0) | NA | 22 (15.7) | 118 (84.3) | 0.046a | 4 (20.0) | 16 (80.0) | NA |
A3F4 (n1 = 11; n2 = 22) | 4 (18.2) | 18 (81.8) | 0 (0.0)4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 22 (100.0) | 0 (0.0) | 0 (0.0) |
Table 5 Logistic regression model predicting moderate and severe (A2A3) degree of liver inflammation
- Citation: Nascimento JCR, Pereira LC, Rêgo JMC, Dias RP, Silva PGB, Sobrinho SAC, Coelho GR, Brasil IRC, Oliveira-Filho EF, Owen JS, Toniutto P, Oriá RB. Apolipoprotein E polymorphism influences orthotopic liver transplantation outcomes in patients with hepatitis C virus-induced liver cirrhosis. World J Gastroenterol 2021; 27(11): 1064-1075
- URL: https://www.wjgnet.com/1007-9327/full/v27/i11/1064.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i11.1064